Catabasis Pharmaceuticals Profile

1.38
USD 0.04  2.99%
9%
71%

Acquisition by Jean George of 14000 shares of Catabasis Pharmaceuticals subject to Rule 16b-3

Catabasis Pharmaceuticals insider trading alert for grant of stock option (right to buy) by Jean George, the corporate stakeholder, on June 7, 2018. This event was filed by Catabasis Pharmaceuticals with SEC on 2018-06-07. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Catabasis Pharmaceuticals Summary

Catabasis Pharmaceuticals (CATB) is traded on NASDAQ General Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 36 people. Catabasis Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Micro-Cap' category with current market capitalization of 38.91 M. Catabasis Pharmaceuticals conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 29.04 M outstanding shares of which 630.21 K shares are currently shorted by private and institutional investors with about 2.68 trading days to cover. N/A currently holds about 17.03 M in cash with (25.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.59.
Check Catabasis Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 1.38HorizonTargetOdds Above 1.38
5.56%30 days 1.38 94.39%
Based on normal probability distribution, the odds of Catabasis Pharmaceuticals to move above current price in 30 days from now is under 95% (This Catabasis Pharmaceuticals probability density function shows the probability of Catabasis Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Sv Health Investors LlcCommon Shares2.9 M5.2 M
Clarus Ventures LlcCommon Shares2 M3.6 M
View Catabasis Pharmaceuticals Diagnostics

Selected Catabasis Pharmaceuticals Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Catabasis Pharmaceuticals Against Markets

Current Ratings

Catabasis Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
1 
Equity ratings for Catabasis Pharmaceuticals are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted linker drug discovery platform in the United States. The company was founded in 2008 and is based in Cambridge, Massachusetts. Catabasis Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ General Markets. It employs 36 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameCatabasis Pharmaceuticals
CEOJill MilneView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
LocationMASSACHUSETTS, U.S.A
Business AddressBuilding 1400E
ExchangeNASDAQ General Markets
CUSIP14875P107
SectorHealthcare
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.catabasis.com
Contact Number617 349 1971
CurrencyUSD - US Dollar

Recommendations

Catabasis Pharmaceuticals Analyst Recommendations
Target PriceAdvice# of Analysts
8.25Buy4Odds
Catabasis Pharmaceuticals current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Catabasis Pharmaceuticals Analyst Advice  

Earnings

Catabasis Pharmaceuticals Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.49March 1, 2017
Catabasis Pharmaceuticals normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Directors

Catabasis Pharmaceuticals Corporate Directors
Jean George Director, MBA
Michael Kishbauch Director, MBA
Burt Adelman Director, Ph.D
Check also Trending Equities. Please also try Aroon Oscillator module to analyze current equity momentum using aroon oscillator and other momentum ratios.